Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I hear you ADXS was the thorn in my investments glty
Yea, I sold after the annual meeting when there wasn't even a glimmer of a rally. Biggest loss of the year for me... Oh well, I have a lot of gains to offset, lol, but I don't like to lose big...
Yeah and it looks like ADXS is on that path.Very sad
Looks like they are guiding to bankruptcy? Sheesh...
Adrian Adams,
Andrew I. Koven,
Jennifer L. Armstrong
Investors need some Guidance - it's overdue
Well, the annual meeting is done... Let's see if any positive vibes will help the stock now....
Just looking for a scalp here
Yep, I averaged down in the .30's, but still have a way to go to get even with this... But it could easily get back to dollarland with a good earnings report...
* * $ARLZ Video Chart 06-13-18 * *
Link to Video - click here to watch the technical chart video
https://seekingalpha.com/article/4172861-aralez-pharmaceuticals-change-strategy-may-bring-silver-lining a lot of these have been running to the 200sma on the daily chart lately, even on no news. count me in
Morning, Anyone,,, when is annual meeting, TY
Can we get in the .50s of course we will!
I probably need to update the info in the Intro section, as much of it is now inaccurate based on the retreat to Canada...
I'm with you also, but the CEO is suppose to be a turn around Artist, this will be his biggest Painting, they really cut the legs off the stock, quite a surprise, caught everybody buy the short hair, and INSTs. had to sell, I don't think the stock will will get back to the 1.50 or 2.00 area until 2019, if at all. but nothing is impossiable, and this could be his finest hour. annual meeting I belive the 29,of June , could be the steal of a lifetime. Cheers
I still think the company is far from over, but I'll be very interested to see how they move forward from here...
This was Kyle Dennis pick for long term , turn around , he praised the CEO as a Turn Around Specilest , what a surprise, pulling out of the U S was a complete surprise to ALL shareholders, Of Course JKyle hasn't said a word to his flock of Pinguins, after he sold out. so maybe well learn whats on CEO mind at the Annuel Meeting, GLTA
OOPS sorry I was talking about AGRX
Same process though with ARLZ can .36 hold?
I thought .59 would hold this week but no go. Let's see if .58 is really the bottom. Watching to get in once it makes a higher low. Are you in?
I just can't believe it's this low....
IF not, stay away until december30, tax selling started early,
* * $ARLZ Video Chart 05-11-18 * *
Link to Video - click here to watch the technical chart video
* * $ARLZ Video Chart 05-09-18 * *
Link to Video - click here to watch the technical chart video
* * $ARLZ Video Chart 05-08-18 * *
Link to Video - click here to watch the technical chart video
No, they still are well funded, but institutions are bailing here... I may average down vs selling out... GLTA
1st quarter earnings out May 8th.... we should find out if the 2018 road to profits strategy is working then.... stay tuned...
The only contract that I am aware of is the renewal of the VA contract. If you are aware of some others please advise.
sorry it took me so long to get back to you,, Thank you very much, the stock had a nice day after straight down from 2.00 , I appreciate your research and the question I have is , was there any press release yet or if you have any idea how much these contracts are would you mind to keep me informed, I have about 75 clients that I put into the stock and would love to give some good news, again thanks so much. Cheers
Some BIG contracts for the Metoprolol XL (Toprol)...
Whats going on here, did all of Kyle Dennis subscribers all sold out. ????
I dunno... at least wait for 1st quarter earnings report...
The CEO is suppose to be a Turn Around specialist, he is ,he took a good stock and turned it into a POS.. Kyle Dennis has all his 800 subscribers in it at 2.00 $$$ he should keep to scalping his subscribers, INSY is another call of his at 85.00 $$$
The stock is rebounding after the earnings disappointment selloff... Investors are now focused on remaining products and forward projections.
Power hour will be amazing if we break the open! Very bullish on $ARLZ
I think the sell off is a knee jerk reaction due to discontinuing there Yosprala drug. The increase in the quarterly loss was the right off of the fair value of Yosprala. Otherwise, we might have missed the projected loss by only .03. Next quarter should be much better. JMHO
Earnings out and no posts? Anyone interested in this one? thoughts on the earnings? ON the guidance?
Question doc.
" REVENUES will increase 50% from 100 million dollars in 2017 to 150 million dollars in 2018! And the company will go from EBDITA neutral in 2017 to about 50 MILLION DOLLARS in 2018! "
SO revenues of $100 million got them break even. But if revenues go up to 4150 million, they should earn $50 million EBDITA? How is that? the first $100 million cost about $100 million, and yet the next $50 million in revenues will be done with ZERO expenses against it, leaving it all as profit?
Doesn't seem feasible. What am I missing here? Do you think they will net $50 million in 2018? Curious. Let me know your thoughts. Doing my DD now, and input is always still a good way to hear what others think as well. thanks.
NEWS - Earnings out March 13th... The stock should run into earnings as I expect some very nice results.... That Lannett metoprolol ER is selling VERY WELL!
I like how 1.70 held up this morning and more volume coming in. It looked like it wanted to break the trend line but the Bulls said no. Will it hold up through the rest of the day? A bullish engulfing candle on the daily would be great going into next week. Looking for a close above 1.76! Bullish on $ARLZ
So Broadfin Healthcare Master Fund is out... that means he was selling over the past few months, so this may be a sign that some overhang is gone?
Very nice to see this forecast
DD ALSo let me go on Record with you, I firmly believe knowing the CEO and studying his management past , I will say that ARLZ will be bought out buy a Major Biotech, Company before you see 10.00 within 2018, The NYC. Show on Feb. 12 and 13th will be huge to showcase themselves to WALL STREET. Cheers
Morning, agree with your long term thinking, CEO, is a guy that's a Company builder and has a vision of making ARLZ a stand out for not only his management team buy the Loyal shareholders that jump on his train and believe his management style, I'm taking any selling, is a signal to me to Add to my position for the future.
Followers
|
26
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
470
|
Created
|
02/05/16
|
Type
|
Free
|
Moderators |
Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada, Ireland, and the United States. It engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas. It offers Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia; Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Fiorinal and Fiorinal C for the relief of tension type headaches; Soriatane, a retinoid, an aromatic analog of vitamin A for the treatment of severe psoriasis and other disorders of keratinization; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. It also markets NeoVisc, a sodium hylauronic solution; Uracyst, a sodium chondroitin sulfate; Durela, a tramadol hydrochloride; Proferrin, a heme iron polypeptide; Resultz, a isopropyl myristate; Collatamp G, a collagen-gentamycin; and a portfolio of eight products targeted for the areas of gastroenterology and women?s health. In addition, it develops YOSPRALA 81/40 and 325/40 for secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers, which have completed Phase III clinical development in the United States; and Bilastine, an antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria. Further, its out-licensed products include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company is headquartered in Milton, Canada.
Aralez Pharmaceuticals Inc.’s ISS Governance QualityScore as of March 2, 2017 is 6. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 4; Compensation: 9.
151 Steeles Avenue East
Milton, ON L9T 1Y1
Canada
905-876-1118
http://www.aralez.com
Sector:
Industry:
Full Time Employees:
Name | Title | Pay | Exercised | Age |
---|---|---|---|---|
Mr. Adrian Adams | Chief Exec. Officer and Director | 1.02M | N/A | 66 |
Mr. Andrew I. Koven | Pres and Chief Bus. Officer | 683.18k | N/A | 59 |
Mr. Scott J. Charles | Chief Financial Officer | 653.07k | N/A | 42 |
Mr. Mark A. Glickman | Chief Commercial Officer | 504.94k | N/A | 51 |
Mr. John E. Barnhardt CPA | Principal Accounting Officer and VP of Fin. & Admin. | N/A | N/A | 67 |
SHARE THIS ARTICLE
-First Quarter 2017 Net Revenues of $26.0 Million-
-Cost Savings Plan Expected to Reduce 2017 Expenses by $23.0 Million; Improved 2017 Adjusted EBITDA Guidance-
-Currently Implementing a Bold Program Aimed at Allowing All Patients to Access Yosprala for Only $10.00 Per Month-
MISSISSAUGA, Ontario, May 9, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (Aralez or the Company) today announced financial results for the first quarter ended March 31, 2017. The Company also highlighted certain recent corporate and commercial achievements. All figures are in U.S. dollars.
"We are pleased to report a solid first quarter of 2017, together with important updates to our business addressing a number of the challenges we face," said Adrian Adams, Chief Executive Officer of Aralez. "We are making a bold and significant change to our pricing strategy for Yosprala® aimed at allowing all patients to access the product for only $10.00 per month. In addition, we continue to implement our cost savings plan to further improve our cost structure and balance sheet to maximize and preserve our financial flexibility. Our updated financial guidance for 2017 reflects our commitment to reaching break-even on an Adjusted EBITDA basis this year. We also continue to opportunistically look at business development opportunities with a strong focus on value creating and transformative M&A with the goal of enhancing shareholder value."
Company Highlights:
"Deerfield Partners remains fully supportive of Aralez and its management team as the company navigates its way through recent challenges," said James Flynn, Managing Partner at Deerfield. "We are encouraged by the new pricing strategy for Yosprala and the prospects for Zontivity."
Cost Savings Initiatives
The Company previously announced in April 2017 that it had begun implementing cost savings initiatives as part of the Company's ongoing objective to maximize value from its assets and preserve financial flexibility. The total expected operating expense reduction in 2017 of approximately $23.0 million includes the previously announced 32% reduction in its U.S. sales force, which is expected to yield 2017 savings of approximately $5.5 million ($7.5 million on an annual basis), a decrease of approximately $9.0 million in 2017 commercial spend, which primarily relates to non-direct marketing spend on Yosprala, and decreased 2017 departmental expenses across the business of approximately $8.5 million. While Aralez has made significant reductions to its expenses, the Company plans to invest an additional $7.0 million to support a successful phased launch of Zontivity that commenced on April 24, 2017, which the Company views as an increasingly attractive opportunity. The Company also continues to assess various business development opportunities with the goal of providing improved cash flow and an enhanced platform for creating value.
First Quarter 2017 Financial Results
Aralez's financial results for the three months ended March 31, 2016 include the operations of Tribute Pharmaceuticals Canada Inc. (Tribute) from February 5, 2016, the closing date of the Pozen and Tribute merger transaction (the Merger), through March 31, 2016, but do not include the results of Zontivity or Toprol-XL and its currently marketed authorized generic (the Toprol-XL franchise) as these acquisitions were completed on September 6, 2016 and October 31, 2016, respectively. Aralez's financial results for the three months ended March 31, 2017 include the results of Tribute, Zontivity and the Toprol-XL franchise.
Total revenues for the three months ended March 31, 2017 were $26.0 million compared to $8.1 million for the three months ended March 31, 2016. Net product revenues of $6.7 million for the three months ended March 31, 2017 primarily related to the product portfolio acquired with the acquisition of Tribute as well as net product revenues from Yosprala and Fibricor®. Other revenues of $19.3 million for the three months ended March 31, 2017 were comprised of net revenues of $15.6 million from the acquisitions of the Toprol-XL franchise and Zontivity, which are recorded net of related cost of product revenues and fees paid during the respective transition service periods, and Vimovo® royalties of $3.7 million. Pursuant to the Company's agreement with Horizon in the U.S., subject to certain conditions described in our public filings, Aralez is guaranteed a quarterly minimum royalty amount (calculated based on a minimum annual royalty of $7.5 million), which was reflected in the Company's first quarter results. Net product revenues of $3.6 million for the three months ended March 31, 2016 related to the Tribute product portfolio acquired in the Merger, which was completed on February 5, 2016. Other revenues of $4.5 million for the three months ended March 31, 2016 were comprised solely of Vimovo royalties.
Cost of product revenues were $2.8 million for the three months ended March 31, 2017 compared to $2.5 million for the three months ended March 31, 2016. The increase related primarily to costs of product revenues for the full quarter in 2017 from the Company's product portfolio that was acquired as part of the Merger in February 2016.
SG&A expenses were $30.8 million for the three months ended March 31, 2017 compared to $37.5 million for the three months ended March 31, 2016. The decrease in SG&A expenses was primarily driven by costs related to the Merger in the prior year of approximately $19.4 million, partially offset by increased costs related to the build out of our U.S. sales force in 2016 and increased promotional expenses in the U.S. during the first quarter of 2017.
R&D expenses for the three months ended March 31, 2017 were $0.1 million compared to $4.4 million for the three months ended March 31, 2016. The decrease related primarily to higher costs incurred in the first quarter of 2016 for Yosprala in advance of its U.S. approval in September 2016.
Amortization of intangible assets of $8.5 million for the three months ended March 31, 2017 related to the acquisitions of Tribute, Zontivity and the Toprol-XL franchise. Amortization of intangible assets for the three months ended March 31, 2016 of $1.3 million related solely to the acquisition of Tribute.
The change in fair value of contingent consideration of $4.4 million for the three months ended March 31, 2017 related to accretion for the Toprol-XL franchise and Zontivity acquisitions. There was no expense related to fair value changes in contingent consideration for the three months ended March 31, 2016.
Interest expense of $6.7 million for the three months ended March 31, 2017 was primarily attributable to the borrowing of $200 million under the Company's credit facility in the fourth quarter of 2016 in connection with the acquisitions of Zontivity and the Toprol-XL franchise and $75 million convertible notes. Interest expense of $0.3 million for the three months ended March 31, 2016 related to the $75 million convertible notes.
Other income, net for the three months ended March 31, 2017, was $0.4 million compared to $4.8 million for the three months ended March 31, 2016, a decrease of $4.4 million. The decrease principally related to a $4.6 million decrease in the fair value of the warrants liability acquired from Tribute during the prior year, offset by a $0.3 million gain from the sale of a building in London, Ontario during the three months ended March 31, 2017.
The net loss for the three months ended March 31, 2017 was $27.5 million, or $0.42 loss per share on a fully diluted basis, compared to a net loss for the three months ended March 31, 2016 of $33.8 million, or $0.73 loss per share on a fully diluted basis.
Adjusted EBITDA was ($3.6) million for the three months ended March 31, 2017 compared to Adjusted EBITDA of ($11.1) million for the three months ended March 31, 2016.
Balance Sheet
As of March 31, 2017, approximately 65.8 million of the Company's common shares were issued and outstanding and the Company had cash and cash equivalents of approximately $73.7 million.
Updated 2017 Guidance
Aralez's estimates are based on projected results of the Company for the year ending December 31, 2017 and reflect management's current beliefs and expectations about, among other things, prescription trends, competition, pricing levels, inventory levels, and anticipated future events. The Company's guidance on Adjusted EBITDA includes, among other things, costs to support the commercialization efforts with respect to Yosprala, Zontivity and the Canadian product portfolio as well as costs to support the global corporate structure. It excludes share-based compensation expense and certain discrete costs, including merger and product acquisition-related expenses. See "Use of Non-GAAP Financial Measures" below.
For the year ending December 31, 2017, assuming, among other factors more particularly set out in "Cautionary Note Regarding Forward-Looking Statements" below, the Company currently expects:
See the table below for a comparison of the Company's original 2017 guidance compared to the updated 2017 guidance:
Measure | 2017 Original Guidance | 2017 Updated Guidance |
Net Revenues | $80 million to $100 million | $80 million to $100 million |
Adjusted EBITDA | $(25) million to $(10) million | $(5) million to $5 million |
First Quarter Results Webcast
Aralez will host a webcast this morning, May 9, 2017 at 9:00 a.m. ET to present results for the first quarter 2017. The webcast can be accessed live and will be available for replay at www.aralez.com.
Conference Call Details
Date: Tuesday, May 9, 2017
Time: 9:00 a.m. ET
Dial-in (U.S.): 877-407-8037
Dial-in (International): 201-689-8037
About Aralez Pharmaceuticals Inc.
Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Aralez's Global Headquarters is in Ontario, Canada, the U.S. Headquarters is in Princeton, New Jersey and the Irish Headquarters is in Dublin, Ireland. More information about Aralez can be found at www.aralez.com.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |